A pH-responsive crosslinker platform for antibody-drug conjugate (ADC) targeting delivery

Chem Commun (Camb). 2022 Sep 20;58(75):10532-10535. doi: 10.1039/d2cc03052g.

Abstract

We report a new 1-6 self-immolative, traceless crosslinker derived from the natural product gallic acid. The linker acts through a pH-dependent mechanism for drug release. This 5-(hydroxymethyl)pyrogallol orthoester derivative (HMPO) was stable for 24 hours at pH values of 7.4 and 6.6 and in plasma, releasing molecules bound to the hydroxymethyl moiety under acid-dependent stimuli at pH 5.5. The linker was non-toxic and was used for the conjugation of Doxorubicin (Doxo) or Combretastatin A4 with Cetuximab. The ADCs formed showed their pH responsivity reducing cell viability of A431 and A549 cancer cells better than Cetuximab alone.

MeSH terms

  • Biological Products*
  • Cell Line, Tumor
  • Cetuximab / pharmacology
  • Doxorubicin / pharmacology
  • Gallic Acid / pharmacology
  • Hydrogen-Ion Concentration
  • Immunoconjugates* / chemistry
  • Immunoconjugates* / pharmacology
  • Pyrogallol

Substances

  • Biological Products
  • Immunoconjugates
  • Pyrogallol
  • Gallic Acid
  • Doxorubicin
  • Cetuximab